psycho-pharma schreef:
Yahoo
Re: ny times on insm sat morn: (1 Rating) 16 minutes ago Very important points are acknowledged and made public for the first time:
1. Iplex is FIRST CHOICE for doctors (convenience + risk, one shot and less risk of hypoglycemia)
2. Iplex is also FIRST CHOICE for patients (Ms. Mullins, who lives in Palm Bay, Fla., said she might not want to put Salem on the Tercica drug if the side effects like hypoglycemia are worse. “I’d rather he be short than have bad side effects,”)
3. Doctors hate what is going on and that is very damaging for TRCA and INCRELEX( Dr. Desrosiers, who HAS BEEN AN ADVISOR TO TERCICA but favors Insmed’s drug, said he wished the dispute would go away. “I wish they wouldn’t eat each other, whoever wins,”)
After reading the article one is left with a strong impression that Iplex will take the whole US market if not enjoined.
TRCA would be left with nothing once patents expire and E.Coli is abandoned as expression medium (no more royalties and just a small market share in the US).
Both parties know INSM will fight to the bitter end to revoke DNA´s controversial patents. DNA has everything to lose and nothing to gain.
A settlement is on the works and it will be favourable to both parties, but particularly INSMED.
P.